INDP

Business Context and Reporting Period

Company: Indaptus Therapeutics, Inc. (INDP)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Indaptus is a clinical-stage biotechnology company developing Decoy20, a novel, multi-targeted immunotherapy for unresectable or metastatic solid tumors and lymphomas. The company has no approved products and has not generated revenue from product sales.

Key Financial Metrics

Note: All share and per-share data has been retroactively restated for a 1-for-28 reverse stock split effected on June 26, 2025.

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses for the nine months ended September 30, 2025, were $11.68 million, a 4.3% increase compared to $11.19 million in the same period in 2024.
  • R&D Expenses: Increased by 36.1% ($1.72 million) to $6.50 million, driven primarily by higher clinical trial costs ($2.6 million) for the Phase 1 study of Decoy20.
  • G&A Expenses: Decreased by 19.3% ($1.24 million) to $5.18 million, largely due to reductions in stock-based compensation, payroll, and board fees, partially offset by transaction costs related to the June 2025 financing.
• Non-Operating Items: The company recognized a loss of $1.15 million for the nine months ended September 30, 2025, due to the change in fair value of convertible promissory notes. This item was not present in the prior year period.
• Capital Structure: Significant equity activity occurred in 2025, including the conversion of $5.7 million in convertible notes into common stock and pre-funded warrants in July 2025, and multiple equity raises via a Standby Equity Purchase Agreement (SEPA) and an At-The-Market (ATM) offering.

Guidance, Outlook, and Risks

• Going Concern: The company has identified conditions that raise substantial doubt about its ability to continue as a going concern. Management believes current cash resources ($5.8 million) are sufficient to fund operations into the first quarter of 2026. Additional capital will be required to continue clinical development.
• Clinical Progress:
  • Decoy20 Monotherapy: Enrollment in the weekly dosing portion of the Phase 1 trial concluded in May 2025. Early signs of stable disease were observed in some participants.
  • Combination Study: A study combining Decoy20 with Tislelizumab (anti-PD-1) is underway. As of November 2025, six participants were enrolled. Enrollment has been paused pending efficacy evaluations. Three participants showed stable disease at initial assessment, though one subsequently progressed.
• Financing Activities: The company raised approximately $1.75 million under the SEPA and $2.34 million via the ATM offering in the first nine months of 2025. In June 2025, it raised $5.7 million via convertible notes which converted to equity in July 2025.
• Risks: Key risks include the need for additional capital, potential dilution to shareholders, uncertainties in clinical trial outcomes, reliance on third-party manufacturers, and the possibility of failing to achieve regulatory approval or commercial success.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $5.8 million cash balance to fund operations through Q1 2026 and the timeline for the next capital raise.
• Dilution Impact: Assess the impact of recent equity issuances (SEPA, ATM, note conversions) and outstanding warrants (approx. 1.78 million shares) on future share count and ownership dilution.
• Clinical Milestones: Monitor the results of the paused Combination Study and the timeline for re-enrollment or next steps in the Phase 1 trial.
• Expense Management: Review the effectiveness of the cost-reduction plan implemented in May 2025, including the temporary salary reductions and elimination of board fees (discontinued Nov 1, 2025).
• Reverse Split Compliance: Confirm the company's continued compliance with Nasdaq listing requirements following the 1-for-28 reverse stock split.